Ir para o conteúdo principal

Lantern Pharma (NASDAQ: LTRN) — Perfil da empresa, notícias e dados financeiros

Logo de Lantern Pharma
LTRN Lantern Pharma
Lantern Pharma primary media
Perfil da empresa

Lantern Pharma

Lantern Pharma (NASDAQ:LTRN) is a biopharmaceutical firm focused on advancing cancer treatment through artificial intelligence and machine learning to develop personalized therapies. Leveraging its proprietary RADR® platform, Lantern aims to revolutionize oncology drug discovery and development by identifying biomarker-driven therapies. The company is actively involved in a variety of projects aimed at tackling some of the most pressing challenges in cancer treatment, including difficult-to-treat tumors and resistance to current therapies. Lantern Pharma's objectives are centered around transforming cancer patient outcomes through precision medicine, improving the speed and efficiency of drug development, and ultimately bringing more targeted, effective treatments to market.

Resumo

Public USParticipação acionária
2013Ano de fundação
21Funcionários
Dallas, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Dallas, US

Produtos e/ou serviços de Lantern Pharma

  • RADR® - AI-driven drug discovery and development platform enhancing precision oncology treatments.
  • LP-100 (Irofulven) - Novel therapy for prostate cancer resistant to standard care.
  • LP-184 - Next-generation molecule targeting solid tumors, including pancreatic and brain cancers.
  • LP-300 - Drug candidate aimed at improving outcomes in non-small cell lung cancer patients, especially nonsmokers.
  • Collaborative research initiatives designed to leverage AI for faster, more accurate oncology drug development.
  • Strategic partnerships with academic and research institutions to explore new cancer treatment pathways.

equipe executiva do Lantern Pharma

  • Panna SharmaPresident, CEO & Director
  • David R. MargraveCFO & Secretary
  • Kishor Gopaldas BhatiaChief Scientific Officer & Scientific Consultant
  • Peter L. NaraCo-Founder & Advisor
  • Marc C. ChamberlainChief Medical Officer of Starlight Therapeutics

Principais indicadores financeiros

Resultados divulgados pela Lantern Pharma, em USD.

Cap. de mercado
9,6 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-1.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Lantern Pharma
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-18 mi-17,1 mi
0-22,2 mi-20,8 mi
0-17,9 mi-16 mi
0-14,4 bi-14,3 bi